024 - Does BAN2401 Actually Work? Upcoming Subgroup Analyses

in #biotech • 6 years ago

Biogen/Eisai to present updated subgroup analyses on their Phase 2 study looking at their Alzheimer's medicine, BAN2401. This antibody binds to amyloid beta protofibrils, reducing plaques in the brain. In this video, I go through Biogen's original data and talk about the problems parsing the Apoe E4+ patients.

The options market is pricing in a 22 pt move in the stock by Oct 26th.

The CTAD 2018 presentation schedule can be found here:
https://www.eisai.com/news/2018/news201886.html
(Note: I said 24th in the video but it's really the 25th)

#breakingbiotech #biib #biogen #alzheimers
6 years ago in #biotech by
$0.00
    Reply 0